ARISTOTLE RE-LYs on the ROCKET. What&#8217;s new in stroke prevention in patients with atrial fibrillation?

Michał Tendera; Marcin Syzdół; Zofia Parma

Vol 19, No 1 (2012)

Review Article

Submitted: 2013-01-24

Published online: 2012-02-02

View PDF

Download PDF file

Get Citation

ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation?

Michał Tendera, Marcin Syzdół, Zofia Parma

Cardiol J 2012;19(1):4-10.

Vol 19, No 1 (2012)

Review articles

Submitted: 2013-01-24

Published online: 2012-02-02

Abstract

Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa — rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF. (Cardiol J 2012; 19, 1: 4–10)